Wearable, step-counting technologies may provide a new way for physicians to remotely monitor disease severity in patients with pulmonary arterial hypertension.
Gustavo Heresi, MD, MS, Director of the Pulmonary Vascular and Chronic Thromboembolic Pulmonary Hypertension Program, led a new study that challenges the prevailing literature on insulin resistance in individuals with pulmonary arterial hypertension. These findings highlight the importance of metabolic research in PAH and may promote new lines of scientific inquiry, including both pharmacological and dietary approaches, for the treatment of PAH.
This automimmune condition isn’t traditionally associated with cardiac disease, but overt cardiac involvement confers a five-year mortality risk of up to 70%. Experts share screening and treatment guidance.
A new study shows serum chloride can help predict mortality in patients with pulmonary arterial hypertension. Lower level at six-month postdiagnosis is linked to larger left atrium and higher pulmonary wedge pressure.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Patients age 45 and younger with pulmonary arterial hypertension respond better to endothelin receptor blockers, shows a retrospective study. Those older than 65 respond better to phosphodiesterase-5 inhibitors.
This is the first study examining changes in pulmonary artery diameter over time in patients with pulmonary arterial hypertension.
Cleveland Clinic’s Rheumatic Lung Disease Program is currently engaged in three major multicenter trials whose common aim is to improve outcomes for patients with rheumatic disease and pulmonary hypertension or interstitial lung disease.
Since multiple conditions can mimic components of PH, the clinician should think about the patient’s total clinical condition before diagnosing and categorizing it. Proper evaluation and etiologic definition are crucial to providing the appropriate therapy.
Since multiple conditions can mimic components of PAH, the clinician should think about the patient’s total clinical condition before diagnosing and categorizing it. Proper evaluation and etiologic definition are crucial to providing the appropriate therapy.
A recent study compared levels of HDL-C in CTEPH patients with those found in PAH patients and controls and assessed the association between HDL-C and markers of disease severity and survival.